Log in

OTCMKTS:RLMD - Relmada Therapeutics Stock Price, Forecast & News

+0.57 (+1.70 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
Now: $34.14
50-Day Range
MA: $29.61
52-Week Range
Now: $34.14
Volume90,516 shs
Average Volume42,534 shs
Market Capitalization$354.48 million
P/E RatioN/A
Dividend YieldN/A
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:RLMD



Sales & Book Value

Annual SalesN/A



Market Cap$354.48 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics Inc (OTCMKTS:RLMD) issued its earnings results on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter. View Relmada Therapeutics' Earnings History.

Has Relmada Therapeutics been receiving favorable news coverage?

Headlines about RLMD stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Relmada Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Relmada Therapeutics.

What other stocks do shareholders of Relmada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Abeona Therapeutics (ABEO), Nuvectra (NVTR), Otonomy (OTIC), Rigel Pharmaceuticals (RIGL), Sierra Oncology (SRRA), Tesla (TSLA), Lumber Liquidators (LL) and Montage Resources (MR).

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the folowing people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO, Interim CFO & Director (Age 59)
  • Dr. Ottavio V. Vitolo M.D., Sr. VP, Head of R&D and Chief Medical Officer (Age 46)
  • Mr. Michael D. Becker, Consultant (Age 50)
  • Dr. Richard M. Mangano, Consultant (Age 69)
  • Ms. Gina DiGuglielmo, VP & Head of Clinical Operations

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $34.14.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $354.48 million. Relmada Therapeutics employs 3 workers across the globe.View Additional Information About Relmada Therapeutics.

MarketBeat Community Rating for Relmada Therapeutics (OTCMKTS RLMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe RLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel